Browse Studies — Arctuva

Phase 2

PODOMOUNT-Basket, a Phase II, Multicentre, Randomised, 2-arm Parallel-group, Double-blind, Placebo-controlled Basket Trial to Assess Safety, Tolerability, PK, and Efficacy of BI 764198 in Four Proteinuric Kidney Diseases

This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minima…

Proteinuric Kidney Diseases

Estimated

~$10 – $7,500

Boehringer IngelheimNCT07355296

Phase 2

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apoli…

Proteinuric Kidney Disease

Estimated

~$10 – $8,750

Vertex Pharmaceuticals IncorporatedNCT05312879

Phase 1

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer…

Proteinuric Renal DiseaseProteinuric Kidney DiseaseProteinuria+1 more

Estimated

~$10 – $6,250

Brigham and Women's HospitalNCT07224776

Phase 2

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.

Proteinuric Kidney Disease

Estimated

~$10 – $8,750

Maze TherapeuticsNCT06830629